Image iProteos

R&D therapeutic strategies of CNS diseases based on the modulation of protein-protein interactions

Teresa Tarragó
CEO
Twitter | LinkedIn

Laura Mendieta
COO
Twitter | LinkedIn

Presentation

Development Stage of your Startup : Operating and Sales

Iproteos focuses its activity on the Research and Development of new therapeutic strategies based on modulation of protein-ligand (PLI) and protein-protein interactions (PPIs) through non-natural peptides or peptidomimetics. The novel entitties are obtained thanks to the IPRO technology, an innovative platform.

Specifically, at Iproteos we apply the IPRO technology on the search for therapeutic agents.

Furthermore, we seek for partners that are interested on the implementation of the IPRO technology to their biotechnology or pharmaceutical companies. Based on our expertise in the field, Iproteos is your perfect Partner in the discovery of potent and active peptidomimetics for your own targets.

Market

Biopharma

Main customers

Pharma companies

Problem / Customers

R&D therapeutic strategies of CNS diseases based on the modulation of protein-protein interactions